NASH drug treatment development: challenges and lessons
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood. As cardiovascular disease is the predominant cause of mortality in people with NAFLD, future pharmacotherapies for NAFLD must consider associated cardiometabolic risk factors. The successful use of glucose-lowering drugs in the treatment of type 2 diabetes in patients with NAFLD indicates that this strategy is important, and worth developing further. Greater public awareness of NAFLD is needed because collaboration between all stakeholders is vital to enable a holistic approach to successful treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prognosis of people with MASLD is highly dependent on stage of liver fibrosis.
“Since the prognosis of people with MASLD is highly dependent on the stage of liver fibrosis [235,236]”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [236]
The citation lists haven’t been fetched yet
References 125 · Cited by 81
- Authors
- Tilg, H., Byrne, C. D., & Targher, G.
- Affiliations
- Innsbruck Medical University (AT)
- University Hospital Southampton NHS Foundation Trust (GB)
- University of Verona (IT)
- Corresponding author
- Tilg, Herbert
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 8
- Issue
- 10
- Pages
- 943-954
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W4385855990
- Cited by
- 81
- References
- 125
- Citations by year
- 2026: 12 · 2025: 27 · 2024: 39 · 2023: 3
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Institute for Health and Care Research (203319)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, drug development, clinical trial failure, cardiometabolic risk, cardiovascular disease, type 2 diabetes, antidiabetic drugs, obesity, chronic kidney disease
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucose, Humans, Obesity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
